Kymera Therapeutics (KYMR) Non-Current Deffered Revenue (2019 - 2025)
Kymera Therapeutics' (KYMR) quarterly Non-Current Deffered Revenue came in at $11.4 million in Q4 2025, down 18.03% on a QoQ basis from $14.0 million in Q3 2025.
Kymera Therapeutics (KYMR) Non-Current Deffered Revenue (2019 - 2025) Analysis & Trends
Kymera Therapeutics (KYMR) has 7 years of Non-Current Deffered Revenue data on file, last reported at $11.4 million in Q4 2025.
- On a quarterly basis, Non-Current Deffered Revenue changed N/A year-over-year to $11.4 million in Q4 2025; TTM through Dec 2025 was $11.4 million, a N/A change from a year earlier, with the FY2025 full-year figure at $11.4 million, changed N/A from the prior year.
- Non-Current Deffered Revenue for Q4 2025 stood at $11.4 million, down from $14.0 million in the prior quarter.
- Over the last five years, Non-Current Deffered Revenue for KYMR reached as high as $64.7 million in Q1 2021 and fell as low as $3.2 million in Q2 2024.
- Historically, Non-Current Deffered Revenue has averaged $27.6 million across 5 years, with a median of $23.9 million in 2022.
- On a YoY basis, Non-Current Deffered Revenue climbed as much as 4.36% in 2024 and fell as far as 84.38% in 2024.
- Year by year, Non-Current Deffered Revenue stood at $39.3 million in 2021, then decreased by 28.74% to $28.0 million in 2022, then slumped by 40.11% to $16.8 million in 2023, then slumped by 80.98% to $3.2 million in 2024, then soared by 258.73% to $11.4 million in 2025.
- Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $11.4 million in Q4 2025, $14.0 million in Q3 2025, and $3.2 million in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Kymera Therapeutics | 10.77 Bn | 10.11 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 11.44 Mn |
| Sep 30, 2025 | 13.96 Mn |
| Jun 30, 2024 | 3.19 Mn |
| Mar 31, 2024 | 23.78 Mn |
| Dec 31, 2023 | 16.77 Mn |
| Sep 30, 2023 | 16.42 Mn |
| Jun 30, 2023 | 20.42 Mn |
| Mar 31, 2023 | 24.87 Mn |
| Dec 31, 2022 | 28.00 Mn |
| Sep 30, 2022 | 21.09 Mn |
| Jun 30, 2022 | 24.07 Mn |
| Mar 31, 2022 | 31.82 Mn |
| Dec 31, 2021 | 39.30 Mn |
| Sep 30, 2021 | 49.94 Mn |
| Jun 30, 2021 | 52.67 Mn |
| Mar 31, 2021 | 64.65 Mn |
| Dec 31, 2020 | 77.84 Mn |
| Sep 30, 2020 | 90.31 Mn |
| Dec 31, 2019 | 29.64 Mn |